Journal article
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer
International journal of clinical oncology, Vol.16(3), pp.264-269
06/01/2011
DOI: 10.1007/s10147-010-0179-x
PMID: 21240683
Abstract
The aim of this study was to assess the early effects of zoledronic acid (ZOL) and oral ibandronate (IBA) on the bone resorption marker s-CTX (serum C-telopeptide of collagen type I) and the bone formation marker B-ALP (bone-alkaline phosphatase) in patients with bone metastases from non-small cell lung cancer (NSCLC).
Fifty-five patients with at least one site of bone metastasis secondary to NSCLC were randomly assigned to receive intravenous ZOL 4 mg every 4 weeks, or oral IBA 50 mg/day.
At 1 month of treatment, s-CTX was reduced by 54.8% (95% CI 40.4-59.8%) in the ZOL group (26 evaluable patients) compared with 38.2% (95% CI 29.8-48.7%) in the oral IBA group (27 evaluable patients) (p = 0.03). At 3 months, s-CTX was reduced by 72.6% (95% CI 58.6-71.3%) in the ZOL group, compared with 66.4% (95% CI 54.3-79.5%) in the oral IBA group (p = 0.22). Both bisphosphonates similarly decreased the bone marker B-ALP at 1 month (ZOL 24.7%, 95% CI 3.6-39.5%, and IBA 24.2%, 95% CI 2.8-43.4%) and 3 months (ZOL 28.6%, 95% CI +2.8-43.3%, and IBA 24.2%, 95% CI 3.2-47.4%). Both bisphosphonates were well tolerated.
Considering the changes in bone markers, ZOL and oral IBA show comparable efficacy in patients with NSCLC and bone metastases.
Details
- Title: Subtitle
- Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer
- Creators
- Filippo Francini - University of SienaAlessandra Pascucci - University of SienaGianluca Bargagli - University of SienaEdoardo Francini - University of SienaRaffaele Conca - University of SienaSalvatora Tindara Miano - University of SienaIgnazio Martellucci - University of SienaCristina Migali - University of SienaGiuseppe Gotti - University of SienaAnna Ida Fiaschi - University of SienaAnnunziata Cozzolino - University of SienaRoberto Petrioli - University of Siena
- Resource Type
- Journal article
- Publication Details
- International journal of clinical oncology, Vol.16(3), pp.264-269
- DOI
- 10.1007/s10147-010-0179-x
- PMID
- 21240683
- NLM abbreviation
- Int J Clin Oncol
- ISSN
- 1341-9625
- eISSN
- 1437-7772
- Publisher
- Springer Nature
- Number of pages
- 6
- Language
- English
- Date published
- 06/01/2011
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221245502771
Metrics
1 Record Views